Head-to-head · WeighScore
bmiMD vs YourHealthRx
By GLP-1 ScorecardUpdated
Score comparison
bmiMD has the higher recorded score — 79.2/100 to 69.6/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | YourHealthRx |
|---|---|---|
| WeighScore | 79.2/100 | 69.6/100 |
| Grade | C+ | C |
| Site position | #29 | #136 |
| Semaglutide | $159/mo month-to-month ($119/mo equivalent with $1,428 prepaid for 12 months) | $170/mo (compounded) |
| Tirzepatide | $249/mo month-to-month ($179/mo equivalent with $2,148 prepaid for 12 months) | $210/mo (compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #29 · C+
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $119 and $179 monthly equivalents require $1,428 or $2,148 paid upfront for 12 months
- A struck-through $228.60 and $349.20 sit above the ladders under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Site position #136 · C
Strengths
- Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
- Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
- Flat subscription price that doesn't change as your dose increases (no titration penalty)
- Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
- Transparent, education-first positioning with published medical disclaimer, privacy, and terms
What to consider
- Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
- Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
- Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
- No LegitScript certification displayed
Featured provider
bmiMD
bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.